Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents.

The effective management of irritability is a key need in young people with autism spectrum disorder (ASD). We evaluated the efficacy and safety of brexpiprazole in children and adolescents with irritability associated with ASD. This was an 8-week, phase 3, randomized, double-blind, placebo-controlled trial (NCT04174365) and 26-week, open-label extension (OLE, NCT04258839) of brexpiprazole (0.

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single- and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo.

Influence of African American elders' age stereotypes on their cardiovascular response to stress.

Although it has been shown that White elders are vulnerable to the influence of age stereotypes, it was not known whether this effect applied to African American elders. In the present study, African American elders were randomly assigned to negative or positive implicit-age-stereotype groups. Compared to participants in the positive age-stereotype group, those in the negative age-stereotype group demonstrated significantly more elevated cardiovascular response to stress, as measured by blood pressure and heart rate following mental challenges.

The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk in Alzheimer's disease.

Alzheimer's disease (AD) is generally understood as primarily affecting cognition while sparing motor function, at least until the later stages of the disease. Studies reported over the past 10 years, however, have documented a prevalence of falls in AD patients significantly higher than in age-matched normal elders; also persons with AD have been observed to have different walking patterns with characteristics that increase gait instability. Recent work in cognitive neuroscience has begun to demonstrate the necessity of intact cognition, particularly executive function, for competent motor control.

Influence of executive function on locomotor function: divided attention increases gait variability in Alzheimer's disease.

Objectives: To evaluate how cognitive function and divided attention affect gait in Alzheimer's disease (AD).

Design: Cross-sectional intervention study with subjects serving as their own controls.

Setting: Inpatient unit and outpatient clinic for patients with dementia located at a Veterans Affairs Medical Center.